Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | BID | P55957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17591101 | 0.80 | CYP3A4 (0.39) | HRH3TDP1L3MBTL1LIPGKCNH2 | |
| SCHEMBL3261204 | 0.78 | TLR8 (0.39) | HRH3TDP1L3MBTL1LIPGMEN1 | |
| SCHEMBL11765109 | 0.78 | HRH3 (0.40) | HRH3TDP1L3MBTL1LIPGALOX15 | |
| SCHEMBL324955 | 0.78 | ALOX5 (0.41) | TDP1LIPGALOX15MEN1TP53 | |
| SCHEMBL31287983 | 0.77 | HCAR2 (0.41) | TDP1ALOX15MEN1TP53CYP3A4 | |
| SCHEMBL13331949 | 0.75 | KCNH2 (0.35) | HRH3KCNH2HCAR2 | |
| SCHEMBL10674805 | 0.74 | GAA (0.37) | L3MBTL1MEN1MAPTTSHRHTT | |
| SCHEMBL8235993 | 0.73 | HRH3 (0.42) | HRH3ALOX15CYP3A4 | |
| SCHEMBL6850310 | 0.73 | CYP3A4 (0.44) | HRH3CYP3A4HCAR2 | |
| SCHEMBL4372160 | 0.73 | PARP1 (0.38) | ALOX15MAPTHCAR3HCAR2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-06-16 | — | — | US | disclosed |
| EP-3946320-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| WO-2021202830-A2 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3849546-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2021-05-20 | — | — | US | disclosed |
| EP-3773670-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2021-01-07 | — | — | US | disclosed |
| EP-3723811-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2310377-B1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA TAU RES SWITZERLAND SA (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2655345-B1 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY | SIGMA TAU RES SWITZERLAND SA (CH) | 2015-02-18 | — | — | EP | disclosed |
| US-20140329812-A1 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2655345-A1 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY | SIGMA-TAU Research Switzerland S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-8383616-B2 | Aryl isoxazole compounds with antitumoural activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2013-02-26 | — | — | US | disclosed |
| WO-2012084602-A1 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110245221-A1 | ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2011-10-06 | — | — | US | disclosed |
| EP-2310377-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA-TAU Research Switzerland S.A. (CH) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010000748-A1 | 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDES MODULATING HSP90 WITH ANTITUMORAL ACTIVITIES | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| EP-0388691-A1 | Azole-1-alkanamides as antiarrhytmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329812-A1 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY | HSP90AB1, HSP90AB2P, HSP90AA1 | HRH3 2043/4885TDP1 2771/4885L3MBTL1 4157/4885 |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HRH3 3918/4885TDP1 1108/4885L3MBTL1 992/4885 |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | HRH3 3927/4885TDP1 1077/4885L3MBTL1 652/4885 |
| US-20110245221-A1 | ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES | HSP90AB1, HSP90AB2P, HSP90AA1 | HRH3 3427/4885TDP1 3306/4885L3MBTL1 4257/4885 |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | HSP90AB1, HSP90AA1, HSP90B1 | HRH3 3918/4885TDP1 1108/4885L3MBTL1 992/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HRH3 3918/4885TDP1 1108/4885L3MBTL1 992/4885 |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | HRH3 3791/4885TDP1 1091/4885L3MBTL1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.